TABLE 4.
Adverse Drug Eventsa
| Product | Major ADR (%) | Minor ADR (%) | Placebo-Adjusted Minor ADR (%) |
| Tofacitinib | 1.50 | 4.50 | 4.50 |
| Adalimumab | 2.49 | 17.00 | 4.32 |
| Etanercept | 2.01 | 13.00 | 4.18 |
| Certolizumab | 3.72 | 6.00 | 9.90 |
| Tocilizumab | 2.69 | 6.00 | 3.30 |
| Rituximab | 1.84 | 2.00 | 3.77 |
| Abatacept | 1.51 | 5.00 | 4.40 |
Sources: Major ADRs: Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis clinical trials.36 Minor ADRs: U.S. prescribing information for each product.13,22,37-41
aRate of adverse drug events are presented at 6 months for each therapy option. ADR = adverse drug reaction.
Unit Costs and Resource Use